NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025

Concepts

• pharmaceutical products
• medical retinal vascular services
• retinal vein occlusion
• medical retinal vascular treatments
• nhs national framework
• medical retinal vascular anti veg-f
• nhs
• national
• medical
• retinal

Location

United Kingdom:

Geochart for 1 buyers and 0 suppliers

NHS England

+−

Leaflet | Map tiles by Stamen Design, under CC BY 3.0. Data by OpenStreetMap, under ODbL.

Description

Provision of Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • proliferative diabetic retinopathy (PDR) • visual impairment due to diabetic macular oedema (DME) • visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy • vision impairment associated with chronic diabetic macular oedema, (DME) • visual impairment due to myopic choroidal neovascularisation (myopic CNV) • retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease • inflammation of the posterior segment of the eye presenting as non-infectious uveitis • prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye

CPV Codes

• 33600000 - Pharmaceutical products
• 33690000 - Various medicinal products

Indicators

• Renewals are available.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. **